TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.
Industry, Sector and Symbol
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Phone+1-919-7658400
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
TransEnterix (NYSEAMERICAN:TRXC) Frequently Asked Questions
What is TransEnterix's stock symbol?
TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."
How were TransEnterix's earnings last quarter?
TransEnterix, Inc. (NYSEAMERICAN:TRXC) issued its quarterly earnings results on Tuesday, February, 26th. The medical instruments supplier reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by $0.01. The medical instruments supplier had revenue of $7.50 million for the quarter, compared to analyst estimates of $7.35 million. The company's revenue was up 120.6% on a year-over-year basis. View TransEnterix's Earnings History.
When is TransEnterix's next earnings date?
What price target have analysts set for TRXC?
3 analysts have issued twelve-month price objectives for TransEnterix's stock. Their forecasts range from $5.00 to $5.50. On average, they anticipate TransEnterix's stock price to reach $5.25 in the next twelve months. This suggests a possible upside of 167.9% from the stock's current price. View Analyst Price Targets for TransEnterix.
What is the consensus analysts' recommendation for TransEnterix?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TransEnterix.
What are Wall Street analysts saying about TransEnterix stock?
Here are some recent quotes from research analysts about TransEnterix stock:
- 1. According to Zacks Investment Research, "TransEnterix Inc. designs, develops and manufactures medical-devices. It offers SPIDER(R) Surgical System, a laparoscopic surgical platform that allows intra-abdominal triangulation procedures to be performed with articulating instruments through a single site. The company is primarily focused on the development and commercialization of SurgiBot, a patient-side minimally invasive surgical robotic system. TransEnterix Inc., formerly known as SafeStitch Medical, Inc., is based in United States. " (1/11/2019)
- 2. BTIG Research analysts commented, "with TransEnterix announced the acquisition of MST Israeli company that has created an image analytics technology that uses artificial intelligence, scene recognition, and machine learning. With the cash + stock transaction (worth ~$33M as of 9/21 closing price) expected to close in Q4, TRXC will pick up the IP portfolio (30 patents, 31 pending), technology assets, and MST’s employees. Though the co’s AutoLap platform has FDA 510(k) and CE Mark clearance, TRXC does not intend to sell it as a standalone product. Instead, its capabilities— including dynamic 3D digital measurement, auto zoom, and anatomical structure identification—will be integrated into Senhance. Timing for these enhancements is unclear, though it is likely to take quarters, not years. We see this as an exciting step toward advanced digital laparoscopy, but our near-term focus remains on system sales." (9/25/2018)
Has TransEnterix been receiving favorable news coverage?
Media headlines about TRXC stock have been trending somewhat positive on Friday, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. TransEnterix earned a coverage optimism score of 1.8 on InfoTrie's scale. They also assigned news headlines about the medical instruments supplier a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the near term.
Are investors shorting TransEnterix?
TransEnterix saw a decline in short interest during the month of April. As of April 15th, there was short interest totalling 35,859,020 shares, a decline of 7.4% from the March 29th total of 38,726,892 shares. Based on an average daily volume of 2,318,969 shares, the short-interest ratio is currently 15.5 days. Currently, 20.0% of the shares of the stock are sold short. View TransEnterix's Current Options Chain.
Who are some of TransEnterix's key competitors?
Some companies that are related to TransEnterix include Nanosonics (NAN), Advanced Medical Solutions Group (AMS), Clover (CLV), CRH Medical (CRH), Bovie Medical (BVX), Bovie Medical (BVX), CRH Medical (CRHM), CRH Medical (CRHM), Tristel (TSTL), SDI (SDI), InfuSystem (INFU), Daxor (DXR), TSO3 (TOS), IsoRay (ISR) and IsoRay (ISR).
What other stocks do shareholders of TransEnterix own?
Who are TransEnterix's key executives?
TransEnterix's management team includes the folowing people:
- Mr. Todd M. Pope, CEO, Pres & Director (Age 53)
- Mr. Joseph P. Slattery, Exec. VP, CFO & Principal Accounting Officer (Age 53)
- Mr. Anthony Fernando, COO, CTO & Exec. VP (Age 46)
- Mr. Joshua B. Weingard, Chief Legal Officer & Sec. (Age 45)
- Dr. Stephanie M. Fitts Ph.D., VP of RA/QA, Clinical and Compliance (Age 52)
Who are TransEnterix's major shareholders?
TransEnterix's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.06%), Enterprise Bank & Trust Co (0.04%), BNP Paribas Arbitrage SA (0.02%), Oppenheimer & Co. Inc. (0.01%) and Whitnell & Co. (0.01%). Company insiders that own TransEnterix stock include Anthony C J Fernando, Joseph P Slattery, Richard C Pfenniger Jr, Todd Pope, Willam N Kelley and William N Starling Jr. View Institutional Ownership Trends for TransEnterix.
Which institutional investors are buying TransEnterix stock?
TRXC stock was bought by a variety of institutional investors in the last quarter, including Enterprise Bank & Trust Co, BNP Paribas Arbitrage SA, Virtu Financial LLC, Whitnell & Co. and Oppenheimer & Co. Inc.. Company insiders that have bought TransEnterix stock in the last two years include Richard C Pfenniger Jr and Willam N Kelley. View Insider Buying and Selling for TransEnterix.
How do I buy shares of TransEnterix?
Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TransEnterix's stock price today?
One share of TRXC stock can currently be purchased for approximately $1.96.
How big of a company is TransEnterix?
TransEnterix has a market capitalization of $425.40 million.
What is TransEnterix's official website?
How can I contact TransEnterix?
TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.
MarketBeat Community Rating for TransEnterix (NYSEAMERICAN TRXC)
MarketBeat's community ratings are surveys of what our community members think about TransEnterix and other stocks. Vote "Outperform" if you believe TRXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRXC will underperform the S&P 500 over the long term. You may vote once every thirty days.
